Study to Evaluate Safety and Efficacy of VX-661 in Combination With Ivacaftor in Subjects With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation With an Open-Label Expansion

A Phase 2, Randomized, Multicenter, Double Blind, Placebo Controlled Study to Evaluate Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of VX-661 in Combination With Ivacaftor for 12 Weeks in Subjects With Cystic Fibrosis, Homozygous for the F508del CFTR Mutation With an Open-Label Extension

The objective of this study was to evaluate the safety and efficacy of VX-661in combination with ivacaftor in participants with cystic fibrosis (CF) who are homozygous for F508del cystic fibrosis transmembrane conductance regulator (CFTR) mutation

Study Overview

• Status: Completed
• Conditions: Cystic Fibrosis
• Intervention / Treatment: Drug: VX-661; Drug: Ivacaftor; Drug: Placebo matched to VX-661; Drug: Placebo matched to Ivacaftor

• Study Type: Interventional
• Enrollment (Actual): 40
• Phase: Phase 2

Contacts and Locations

Study Locations

• United States
  • Alabama
    • Birmingham, Alabama, United States
  • California
    • Palo Alto, California, United States
    • Stanford, California, United States
  • Florida
    • Altamonte Springs, Florida, United States
    • Miami, Florida, United States
    • Orlando, Florida, United States
    • Tampa, Florida, United States
  • Idaho
    • Boise, Idaho, United States
  • Illinois
    • Chicago, Illinois, United States
  • Massachusetts
    • Boston, Massachusetts, United States
  • New Jersey
    • New Brunswick, New Jersey, United States
  • New York
    • New York, New York, United States
  • North Carolina
    • Durham, North Carolina, United States
  • Ohio
    • Cincinnati, Ohio, United States
  • Oklahoma
    • Oklahoma City, Oklahoma, United States
  • Pennsylvania
    • Pittsburgh, Pennsylvania, United States
  • South Carolina
    • Charleston, South Carolina, United States
  • Tennessee
    • Memphis, Tennessee, United States
  • Texas
    • Houston, Texas, United States
  • Vermont
    • Burlington, Vermont, United States
    • Colchester, Vermont, United States
  • Washington
    • Seattle, Washington, United States
  • Wisconsin
    • Milwaukee, Wisconsin, United States

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Homozygous for the F508del CFTR mutation
• FEV1 ≥40% and ≤90% of predicted normal for age, sex, and height
• Stable CF disease as judged by the investigator

Exclusion Criteria:

• History of any comorbidity that, in the opinion of the investigator, might confound the results of the study or pose an additional risk in administering study drug to the participant
• Pregnant and nursing females: Females of childbearing potential must have a negative pregnancy test at screening and Day 1 of the PC Phase and Day -7 or Day 1 of the OLE Phase (whichever was applicable)
• Sexually active participants of reproductive potential who are not willing to follow the contraception requirements
• The participant or a close relative of the participant is the investigator or sub investigator, research assistant, pharmacist, study coordinator, or other staff directly involved with the conduct of the study.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Triple

Number of Arms

5

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: PC Phase: VX-661 50 mg q12h + IVA 150 mg q12h; Participants received VX-661 50 milligram (mg) tablet plus Ivacaftor (IVA) 150 mg tablet every 12 hours (q12h) for 12 weeks.	Drug: VX-661; Tablet, oral use; Drug: Ivacaftor; Film coated tablet, oral use
Placebo Comparator: PC Phase: VX 661 placebo q12h + IVA placebo q12h; Participants received placebo matched to VX-661 tablet plus placebo matched to IVA tablet q12h for 12 weeks.	Drug: Placebo matched to VX-661; Tablet, oral use; Drug: Placebo matched to Ivacaftor; Film coated tablet, oral use
Experimental: PC Phase: VX-661 100 mg qd + IVA 150 mg q12h; Participants received two VX-661 50 mg tablets once daily (qd) plus IVA 150 mg tablet q12h for 12 weeks.	Drug: VX-661; Tablet, oral use; Drug: Ivacaftor; Film coated tablet, oral use
Placebo Comparator: PC Phase: VX -661 placebo qd + IVA placebo q12h; Participants received two placebo matched to VX-661 tablets qd plus placebo matched to IVA tablet q12h for 12 weeks.	Drug: Placebo matched to VX-661; Tablet, oral use; Drug: Placebo matched to Ivacaftor; Film coated tablet, oral use
Experimental: OLE Phase: VX-661 100 mg qd + IVA 150 mg q12h; Participants who completed 12 week PC phase underwent a washout period of at least 4 weeks before entering the OLE phase and received two VX-661 50 mg tablets qd plus IVA 150 mg tablet q12h for 48 weeks in OLE phase.	Drug: VX-661; Tablet, oral use; Drug: Ivacaftor; Film coated tablet, oral use

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
PC Phase: Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)	AE: Any untoward medical occurrence in a participant during the study; the event does not necessarily have a causal relationship with the treatment. This includes any newly occurring event or previous condition that has increased in severity or frequency after the informed consent form is signed. AE includes serious as well as Non-serious AEs. SAE (subset of AE): medical event or condition, which falls into any of the following categories, regardless of its relationship to the study drug: death, life threatening adverse experience, Inpatient hospitalization/prolongation of hospitalization, persistent/significant disability or incapacity, congenital anomaly/birth defect, important medical event. AEs with start date or increased severity on or after the first dose of study drug through the end of study participation considered treatment-emergent. Baseline was defined as Day 1 of PC Phase.	Baseline (PC Phase) up to 112 days
OLE Phase: Number of Participants With Treatment-Emergent AEs and SAEs	AE: Any untoward medical occurrence in a participant during the study; the event does not necessarily have a causal relationship with the treatment. This includes any newly occurring event or previous condition that has increased in severity or frequency after the informed consent form is signed. AE includes serious as well as Non-serious AEs. SAE (subset of AE): medical event or condition, which falls into any of the following categories, regardless of its relationship to the study drug: death, life threatening adverse experience, Inpatient hospitalization/prolongation of hospitalization, persistent/significant disability or incapacity, congenital anomaly/birth defect, important medical event. AEs with start date or increased severity on or after the first dose of study drug through the end of study participation considered treatment-emergent. Baseline was defined as Day 1 of the OLE Phase.	Baseline (OLE Phase) up to 364 days

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
PC Phase: Absolute Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (FEV1) Through Week 12	FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. Baseline was defined as Day 1 of PC Phase.	Baseline (PC Phase), Through Week 12
OLE Phase: Absolute Change From Baseline in Percent Predicted FEV1 Through Week 40	FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. Baseline was defined as Day 1 of the OLE Phase.	Baseline (OLE Phase), Through Week 40
PC Phase: Relative Change From Baseline in Percent Predicted FEV1 Through Week 12	FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. Baseline was defined as Day 1 of PC Phase.	Baseline (PC Phase), Through Week 12
OLE Phase: Relative Change From Baseline in Percent Predicted FEV1 Through Week 40	FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. Baseline was defined as Day 1 of the OLE Phase.	Baseline (OLE Phase), Through Week 40
PC Phase: Absolute Change From Baseline in Sweat Chloride Through Week 12	Sweat samples were collected using an approved collection device. Baseline was defined as Day 1 of PC Phase.	Baseline (PC Phase), Through Week 12
OLE Phase: Absolute Change From Baseline in Sweat Chloride Through Week 40	Sweat samples were collected using an approved collection device. Baseline was defined as Day 1 of the OLE Phase.	Baseline (OLE Phase), Through Week 40
PC Phase: Absolute Change From Baseline in Body Weight at Week 12	Baseline was defined as Day 1 of PC Phase.	Baseline (PC Phase), Week 12
OLE Phase: Absolute Change From Baseline in Body Weight at Week 40	Baseline was defined as Day 1 of the OLE Phase.	Baseline (OLE Phase), Week 40
PC Phase: Absolute Change From Baseline Body Mass Index (BMI) at Week 12	BMI was calculated using following formula: BMI = Weight in kg/height in square meter (m^2). Baseline was defined as Day 1 of PC Phase.	Baseline (PC Phase), Week 12
OLE Phase: Absolute Change From Baseline BMI at Week 40	BMI was calculated using following formula: BMI = Weight in kg/height in m^2. Baseline was defined as Day 1 of the OLE Phase.	Baseline (OLE Phase), Week 40
PC Phase: Absolute Change From Baseline in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score Through Week 12	The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for participants with cystic fibrosis. Respiratory domain assessed respiratory symptoms (for example, coughing, congestion, wheezing), score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life. Baseline was defined as Day 1 of PC Phase.	Baseline (PC Phase), Through Week 12
OLE Phase: Absolute Change From Baseline in CFQ-R Respiratory Domain Score Through Week 40	The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for participants with cystic fibrosis. Respiratory domain assessed respiratory symptoms (for example, coughing, congestion, wheezing), score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life. Baseline was defined as Day 1 of the OLE Phase.	Baseline (OLE Phase), Through Week 40
PC Phase: Maximum Plasma Concentration (Cmax) of VX-661 and IVA		Pre-dose, 2, 3, 4, 6, 9 and 12 hours post-dose on Day 85
PC Phase: Area Under the Concentration Versus Time Curve From Time 0 to 24 Hours (AUC0-24h) of VX-661	Pharmacokinetic (PK) sampling was performed up to 12 hours post-dose on Day 85. For Arm VX-661 50 mg q12h + IVA 150 mg q12h (VX-661 q12h regimen), area under the concentration versus time curve from time 0 to 12 hours (AUC0-12h) was multiplied by 2 to obtain AUC0-24h.	Pre-dose, 2, 3, 4, 6, 9 and 12 hours post-dose on Day 85
PC Phase: Area Under the Concentration Versus Time Curve From Time 0 to 12 Hours (AUC0-12h) of IVA		Pre-dose, 2, 3, 4, 6, 9 and 12 hours post-dose on Day 85
PC Phase: Time to Reach Cmax (Tmax) of VX-661 and IVA		Pre-dose, 2, 3, 4, 6, 9 and 12 hours post-dose on Day 85

Collaborators and Investigators

• Sponsor: Vertex Pharmaceuticals Incorporated

Study record dates

Study Major Dates

• Study Start: March 1, 2014
• Primary Completion (Actual): May 27, 2016
• Study Completion (Actual): May 27, 2016

Study Registration Dates

• First Submitted: February 21, 2014
• First Submitted That Met QC Criteria: February 21, 2014
• First Posted (Estimate): February 25, 2014

Study Record Updates

• Last Update Posted (Actual): April 13, 2018
• Last Update Submitted That Met QC Criteria: March 14, 2018
• Last Verified: March 1, 2018

More Information

Terms related to this study

• Keywords: CF
• Additional Relevant MeSH Terms: Digestive System Diseases; Pathologic Processes; Respiratory Tract Diseases; Lung Diseases; Infant, Newborn, Diseases; Genetic Diseases, Inborn; Pancreatic Diseases; Fibrosis; Cystic Fibrosis; Molecular Mechanisms of Pharmacological Action; Membrane Transport Modulators; Chloride Channel Agonists; Ivacaftor
• Other Study ID Numbers: VX13-661-103